INTRODUCTION
============

Antimicrobial resistance (AMR) is becoming one of the greatest challenges to public health worldwide. Infections by antimicrobial-resistant organisms can result in failure of treatment, increased medical costs, prolonged hospital stays, and an increased socioeconomic burden \[[@b1-kjim-2018-028]\]. Antimicrobial usage remains heavy in Korea, even after much effort to reduce their use \[[@b2-kjim-2018-028],[@b3-kjim-2018-028]\]. The AMR burden in Korea is large, especially due to healthcare-associated infections caused by multidrug-resistant organisms (MDROs) \[[@b4-kjim-2018-028]\].

The discovery of antimicrobials was an epochal advance in 20th century medicine, but the efficacy of most antimicrobials is decreasing progressively with continuously evolving AMR; this could terminate in a 'post-antibiotics era' in which common infections may be lethal with no available treatment options \[[@b5-kjim-2018-028]\]. In August 2016, the Korean Ministry of Health and Welfare established the Korean National Action Plan on AMR \[[@b6-kjim-2018-028]\]. The action plan has six objectives: (1) to promote the prudent use of antimicrobial medicines; (2) to prevent the spread of AMR; (3) to strengthen the surveillance system; (4) to improve awareness; (5) to strengthen research and development; and (6) to enhance international collaboration. Prudent antimicrobial prescriptions, based on evidence and the current epidemiology of AMR, is the key to solving the AMR problem, which is an urgent public health concern.

We reviewed the current epidemiology of MDROs in Korea, focusing on Gram-negative bacilli (GNB), because the recent sharp rise in the isolation of carbapenemase-producing Enterobacteriaceae (CPE) in many Korean healthcare facilities has rendered the infection-control situation in Korea gloomier, in addition to already prevalent carbapenem-resistant *Acinetobacter baumannii* (CRAB) \[[@b7-kjim-2018-028]\]. To make matters worse, the recent increase in colistin resistance is extremely worrisome because colistin is the last line of defense against CPE and CRAB \[[@b8-kjim-2018-028]\].

RECENT ANTIMICROBIAL RESISTANCE RATES OF GRAM-NEGATIVE BACILLI
==============================================================

Accurate nationwide surveillance of antimicrobial-resistant bacteria is becoming more important to establish the optimal treatment guidelines for empirical therapy. The Korean Nosocomial Infections Surveillance System \[[@b9-kjim-2018-028]\], Korean Nationwide Surveillance of Antimicrobial Resistance \[[@b10-kjim-2018-028]\], Korean Network for Study on Infectious Disease, and Korean Antimicrobial Resistance Monitoring System (KARMS) have all played roles in Korea \[[@b7-kjim-2018-028]\]. KARMS was launched by the Korean Center for Disease Control and Prevention (KCDC) in 2002 and reported on the prevalence and characteristics of MDROs from 31 secondary or tertiary hospitals within a finite period. In 2016, the Global Antimicrobial Resistance Surveillance System in Korea was established according to the World Health Organization standards for a global surveillance program to combine patient, laboratory, and epidemiological surveillance data \[[@b11-kjim-2018-028]\].

[Table 1](#t1-kjim-2018-028){ref-type="table"} summarizes the recent KARMS data on Enterobacteriaceae \[[@b7-kjim-2018-028]\]. In 2015, the resistance rates of *Escherichia coli* to ampicillin (72%), ampicillin-sulbactam (45%), cefotaxime (35%), fluoroquinolone (48%), gentamycin (29%), and cotrimoxazole (39%) were high, while the resistance rates to piperacillin-tazobactam (5%), cefoxitin (9%), imipenem (\< 0.1%), and amikacin (1%) were low. For *Klebsiella pneumoniae*, the resistance rates to third-generation cephalosporins are similar to those of *E. coli*, while the resistance rates to piperacillin-tazobactam (21%) and amikacin (5%) are higher, and those to gentamicin (19%) and fluoroquinolone (34%) are lower, than for *E. coli*. The resistance rate of *K. pneumoniae* to tigecycline was 8%. AMRs to major antimicrobials showed no notable change in Enterobacteriaceae between 2013 and 2015.

[Table 1](#t1-kjim-2018-028){ref-type="table"} summarizes the recent KARMS data for non-glucose-fermenting GNB \[[@b7-kjim-2018-028]\]. In 2015, the resistance rates of *A. baumannii* imipenem were very high for piperacillin (86%), piperacillin-tazobactam (82%), cefotaxime (84%), cefepime (83%), imipenem (85%), amikacin (60%), gentamycin (75%), ciprofloxacin (87%), and cotrimoxazole (64%). Only tigecycline (4%) and colistin (\< 0.1%) remain active in *A. baumannii*. For *Pseudomonas aeruginosa*, the degree of resistance to piperacillin (27%), piperacillin-tazobactam (25%), ceftazidime (19%), cefepime (18%), aztreonam (23%), imipenem (35%), amikacin (13%), gentamycin (18%), and ciprofloxacin (34%) was less than that for *A. baumannii*. Colistin activity is also preserved in *P. aeruginosa*. *A. baumannii* is one of the main nosocomial pathogens in intensive care units \[[@b4-kjim-2018-028]\], and the dramatic spread of CRAB has resulted in a lack of adequate therapeutic options, except for colistin \[[@b12-kjim-2018-028]\]. Multidrug-resistant features of *A. baumannii* are a leading threat to immunocompromised hosts and have resulted in high mortality \[[@b13-kjim-2018-028]\].

RESISTANCE MECHANISMS OF ENTEROBACTERIACEAE
===========================================

According to long-term surveillance by KARMS \[[@b7-kjim-2018-028]\], the resistance of *E. coli* to ciprofloxacin has increased steadily since 2004. The cefotaxime-resistance rate has increased markedly since 2008, while the cefoxitin-resistance rate has decreased markedly since 2011. For *K. pneumoniae*, the ciprofloxacin- and cefotaxime-resistance rates have increased since 2004, but not much as in *E. coli*.

This continuous increase in the antimicrobial resistant rates of *E. coli* to third- and fourth-generation cephalosporins since the mid-2000s could be due to the spread of the CTX-M type extended-spectrum-β-lactamase (ESBL)-producing sequence type (ST) 131 clone \[[@b14-kjim-2018-028],[@b15-kjim-2018-028]\]. A recent molecular epidemiology study of ST131 *E. coli* in Korea showed that the ST131 clonal group comprised 21% of all 268 *E. coli* isolates and 37% of 57 ST131 isolates had *H30Rx* subclones, which showed a significant association with ciprofloxacin and cefotaxime resistance \[[@b16-kjim-2018-028]\]. The spread of ESBL-producing *E. coli* to the community is also problematic and the emergence of community-onset bacteremia caused by ESBL-producing *E. coli* has been a concern in Korea \[[@b17-kjim-2018-028]\]. A study that analyzed 213 *E. coli* isolates collected from the community found that 25.8% had CTX-M-type ESBL genes, mainly CTX-M-14 and CTX-M-15, and globally epidemic ST131 clones were found in 27.2% of the *E. coli* isolates \[[@b18-kjim-2018-028]\]. With the rapid expansion and dissemination of the ST131 clone in both healthcare facilities and the community, fluoroquinolone resistance has also increased in *E. coli* because the ESBL-producing ST131 clone shares mutations in the fluoroquinolone resistance-determining gyrA and parC regions \[[@b19-kjim-2018-028]\].

In *K. pneumoniae*, ST11 is the most frequent clone; this is a single-locus variant of the international hyper-epidemic lineage ST258 \[[@b20-kjim-2018-028]\]. The spread of this clone is an emerging threat because the coproduction of carbapenemase (*K. pneumoniae* carbapenemase 2 \[KPC-2\]) and 16S rRNA methylase (*rmtB*), in addition to ESBL, has severely limited antimicrobial therapy \[[@b20-kjim-2018-028]\]. Unlike resistance to aminoglycosides, which is mainly mediated by aminoglycoside modification, 16S rRNA methyltransferase production compromises very potent aminoglycosides with high-level resistance \[[@b21-kjim-2018-028]\]. Resistance to cefoxitin is mediated by AmpC β-lactamase, resulting from overexpression of the chromosomal *AmpC* gene or acquisition of a plasmid-mediated AmpC (pAmpC) determinant \[[@b22-kjim-2018-028]\]. Although *K. pneumoniae* with transferrable *pAmpC* genes was first detected in Korea in 1988 \[[@b23-kjim-2018-028]\], the cefoxitin-resistance rates of *K. pneumoniae* have decreased continuously since 2004 \[[@b7-kjim-2018-028]\].

Carbapenem resistance in Enterobacteriaceae (CRE) can result from two different mechanisms. Some CRE that possess either AmpC β-lactamase or ESBL with concomitant porin mutations can render the organism non-susceptible to carbapenems. More importantly, some CRE may result from the production of carbapenemases that break down carbapenems. Carbapenemases belong to a heterogeneous group of β-lactamases \[[@b24-kjim-2018-028]\]. The class A penicillinase KPC, class B metalloenzyme New Delhi metallo-β-lactamase (NDM), and class D oxacillinase (OXA)-type carbapenemases are found in Enterobacteriaceae worldwide \[[@b25-kjim-2018-028]\]. With the global increase in CRE over the past 10 years, the resistance rate to carbapenem in Enterobacteriaceae remains very low in Korea ([Table 1](#t1-kjim-2018-028){ref-type="table"}). However, the number of CRE isolates increased markedly, from 16 in 2011 to 1,455 in 2016, since KCDC started to monitor CRE in 2010. CRE has also been reported from the community \[[@b26-kjim-2018-028]\]. According to KCDC surveillance data, *K. pneumoniae* is the most common bacterial type of CRE (79.6% of all isolates in 2015 and 83.2% in 2016) and carbapenemases were also detected in *E. coli, Enterobacter spp., Citrobacter spp., Serratia marcescens*, and *Klebsiella oxytoca* \[[@b27-kjim-2018-028]\]. As shown in [Fig. 1](#f1-kjim-2018-028){ref-type="fig"}, the common Korean genetic types of CRE in 2016 were KPC (n = 1,029, 70.7%), NDM (n = 197, 13.5%), OXA-48 (n = 139, 9.6%), Guiana-extended spectrum (n = 45, 3.1%), Verona integron-encoded metallo-β-lactamase (VIM; n = 29, 2.0%), and imipenemase (IMP; n = 16, 1.1%) \[[@b27-kjim-2018-028]\]. This situation is mostly due to the increased incidence of CPE due to an outbreak in major healthcare facilities, rendering it a recent public health issue of South Korea \[[@b27-kjim-2018-028]-[@b29-kjim-2018-028]\].

RESISTANCE MECHANISMS OF NON-GLUCOSE-FERMENTING GRAM-NEGATIVE BACILLI
=====================================================================

The resistance rate of *A. baumannii* to imipenem increased to 85% in 2015 \[[@b7-kjim-2018-028]\], representing a major public threat in Korea. Carbapenem is usually considered a treatment option for ESBL producers and the increased nationwide rate of prescription of carbapenems is correlated with the rapid rise in CRAB isolation since 2007 \[[@b30-kjim-2018-028]\]. OXA-type β-lactamases are the main resistance mechanism for CRAB and a drastic increase in *Acinetobacter* isolates with *bla*~OXA-23~ has been observed since the mid-2000s, whereas ISAba1-associated *bla*~OXA-51~, another contributor to CRAB, has decreased since the mid-2000s \[[@b31-kjim-2018-028]\]. Many CRAB isolates are multidrug-resistant or extensively drug-resistant because they usually co-carry AMR through *armA*/aminoglycosides-modifying enzymes (aminoglycosides), DNA gyrase/topoisomerase IV (fluoroquinolones), and Ade-type efflux pumps (tetracyclines) \[[@b32-kjim-2018-028]\]. Recently, the treatment of carbapenem-resistant *A. baumannii* infection has been severely restricted because the agents of last resort, such as colistin and tigecycline, are losing their efficacy with the emergence of colistin resistance in *A. baumannii*. The colistin-resistant gene of *Acinetobacter* spp. is usually located in the chromosome and the mechanisms of resistance are modification of lipid A by phosphoethanolamine via pmrAB two-component regulatory gene mutations (*pmrA* and *pmrB*) and loss of lipopolysaccharide via inactivation of a lipid A biosynthesis gene (*lpxA, lpxC,* or *lpxD*) \[[@b8-kjim-2018-028]\].

The resistance rate of *P. aeruginosa* to imipenem was 35% in 2015, but no marked rise in resistance was observed in *P. aeruginosa* from 2004 to 2015 \[[@b7-kjim-2018-028]\]. Since the first report of VIM-2-producing *P. aeruginosa* in Korea in 2002 \[[@b33-kjim-2018-028]\], metallo-β-lactamases have been the main mechanism for carbapenem-resistant *P. aeruginosa* in the IMP and VIM types \[[@b34-kjim-2018-028]\]. The rates of amikacin- and gentamicin-resistant *P. aeruginosa* have declined continuously \[[@b7-kjim-2018-028]\] and this is correlated with the Korea-wide reduction in aminoglycoside use \[[@b35-kjim-2018-028]\]. Aminoglycosides, except amikacin, are considered old drugs, but they still play key roles in the treatment of infections, and have potent bactericidal activity against some CRE \[[@b36-kjim-2018-028]\].

TREATMENT OPTIONS FOR ANTIMICROBIAL-RESISTANT GRAM-NEGATIVE BACTERIA
====================================================================

There are relatively few treatment options for CRAB and CRE. Most reports are retrospective observational studies. Because there are little published data from randomized controlled trials, more data on the antimicrobial treatment of CRAB or CRE are needed to make treatment recommendations. The mortality associated with invasive CRAB infection is high and is linked to comorbid disease severity and initial inappropriate antimicrobial therapy \[[@b37-kjim-2018-028]\]. Moreover, infection with, or colonization of, antimicrobial-resistant Gram-negative bacteria is associated with a longer hospital stay and increased medical costs \[[@b38-kjim-2018-028],[@b39-kjim-2018-028]\]. Although extensively drug-resistant (resistant to all but two or less classes) isolates have been reported, the majority of isolates remain susceptible to polymyxin (colistin or polymyxin B). Many retrospective studies and meta-analyses have shown that combination therapy confers a survival advantage over monotherapy \[[@b40-kjim-2018-028]-[@b43-kjim-2018-028]\].

POLYMYXINS
==========

Polymyxins interact with lipid A in the Gram-negative bacterial outer membrane, leading to the leakage of cellular contents and bacterial cell death. With increasing antibiotic resistance among important Gram-negative bacteria and the lack of new antibiotics, old antibiotics discovered in the 1950s have been reintroduced in recent years \[[@b44-kjim-2018-028]\]. Polymyxin B and colistin (polymyxin E) are two polymyxins that can be used. Colistin is administered as the inactive prodrug colistin methanesulfonate (CMS), whereas polymyxin B is administered as an active drug. CMS requires a loading dose of up to 300 mg (colistin base activity) because it has to be converted into colistin in the plasma and patients are otherwise exposed to suboptimal concentrations for several days. Although polymyxin B is not available in Korea, it has superior pharmacological characteristics for treating infections and rapidly and reliably achieves the desired plasma concentration of the active polymyxin \[[@b45-kjim-2018-028],[@b46-kjim-2018-028]\]. Combination therapy with a second active agent or an agent that demonstrates synergy with colistin is recommended. The two major complications associated with polymyxins are nephrotoxicity and neurotoxicity. Approximately 50% of cases manifest variable degrees of nephrotoxicity due to colistin, although these are usually reversible.

CARBAPENEMS
===========

Carbapenems are considered the drug of choice for treating infections caused by multidrug-resistant Gram-negative bacteria due to their excellent activity against these organisms and safety profile. However, there is concern about carbapenem use because of the increasing resistance to them. High-dose meropenem (6,000 mg/day) administered by prolonged (\> 4 hours) infusion had a high probability of target attainment in Monte Carlo dosing simulations \[[@b47-kjim-2018-028]\]. Although the pharmacokinetic data appear favorable \[[@b48-kjim-2018-028]\], therapy with carbapenem alone cannot be recommended because there are limited clinical data. Carbapenem-based combination therapy resulted in relatively low mortality in retrospective studies \[[@b42-kjim-2018-028],[@b49-kjim-2018-028]\]. High-dose, extended infusion of a carbapenem as part of a combination regimen can be considered a viable treatment for carbapenem-resistant organisms.

TIGECYCLINE
===========

Tigecycline is a glycylcycline antimicrobial and a semisynthetic derivative of minocycline. This newly developed antimicrobial inhibits protein synthesis and is bacteriostatic. Tigecycline is approved for the treatment of skin and skin structure infections, complicated intra-abdominal infections, and community-acquired pneumonia. Outcomes with tigecycline monotherapy have not been favorable. High dosing of tigecycline, i.e., increasing the dose of tigecycline to 100 mg twice daily, should be considered because of the low likelihood of reaching target pharmacokinetic/pharmacodynamic parameters with the conventional dose of 50 mg twice daily. Tigecycline should be reserved for cases with no other treatment options due to its black-box warning of increased mortality \[[@b42-kjim-2018-028]\].

COMBINATION THERAPY
===================

Monotherapy for CRE is not better than inappropriate therapy, and combination therapy offers a survival advantage over monotherapy \[[@b42-kjim-2018-028]\]. Moreover, monotherapy can lead to resistance and possible loss of that class of antimicrobials. The combinations associated with the lowest mortality rates contained a carbapenem \[[@b42-kjim-2018-028]\]. Several retrospective studies have documented lower mortality rates after CRAB infection when more than one agent was given for therapy \[[@b40-kjim-2018-028],[@b41-kjim-2018-028]\]. However, it is still controversial whether combined therapy is more effective than monotherapy \[[@b50-kjim-2018-028]\].

CONCLUSIONS
===========

AMR is increasing among Gram-negative bacteria in Korea. Treatment options for drug-resistant Gram-negative bacteria, such as CRE and CRAB, are limited. We are on the cusp of a post-antibiotics era. To optimize treatment, continued research on combination therapy and the dosing of antimicrobials is needed. New drug development, and prolongation of the activity of existing antimicrobials through appropriate use, have become important strategies.
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###### 

Antimicrobial resistance rates (median, %) of major gram-negative bacillus in Korea from 2013 to 2015

  Antimicrobial agents       *Escherichi coli*   *Klebsiella pneumoniae*   *Acinetobacter baumannii*   *Pseudomonas aeruginosa*                                                  
  -------------------------- ------------------- ------------------------- --------------------------- -------------------------- ---- ---- -------- -------- -------- ---- ---- --------
  Ampicillin                 70                  69                        72                          NT                         NT   NT   NT       NT       NT       NT   NT   NT
  Piperacillin               79                  69                        68                          NT                         NT   NT   82       87       86       30   26   27
  Ampicillin-sulbactam       40                  44                        45                          NT                         NT   NT   57       50       46       NT   NT   NT
  Piperacillin- tazobactam   6                   5                         5                           22                         20   21   81       86       82       29   28   25
  Cefotaxime                 29                  32                        35                          40                         41   38   79       86       84       NT   NT   NT
  Ceftazidime                30                  31                        31                          40                         41   36   77       84       83       21   21   19
  Cefepime                   28                  30                        31                          38                         41   33   78       85       83       20   20   18
  Azteronam                  30                  30                        30                          39                         38   35   NT       NT       NT       23   33   23
  Cefoxitin                  9                   10                        9                           17                         12   14   NT       NT       NT       NT   NT   NT
  Imipenem                   \< 0.1              \< 0.1                    \< 0.1                      \< 0.1                     1    1    77       84       85       32   35   35
  Meropenem                  \< 0.1              \< 0.1                    \< 0.1                      \< 0.1                     1    1    77       85       84       24   27   25
  Amikacin                   1                   1                         1                           7                          5    5    45       52       60       13   12   13
  Gentamicin                 29                  30                        29                          19                         20   19   73       76       75       19   20   18
  Fluoroquinolone            42                  45                        48                          34                         35   34   84       88       87       36   30   34
  Cotrimoxazole              38                  38                        39                          21                         24   30   74       75       64       NT   NT   NT
  Tigecycline                NT                  NT                        NT                          5                          6    8    5        2        4        NT   NT   NT
  Colistin                   NT                  NT                        NT                          NT                         NT   NT   \< 0.1   \< 0.1   \< 0.1   1    1    \< 0.1

Modified from data of Korean Antimicrobial Resistance Monitoring System (KARMS) \[[@b7-kjim-2018-028]\].

NT, not tested.

[^1]: This paper was contributed by the Korean Society of Infectious Diseases.
